Get access

FEIBA prophylaxis in haemophilia patients: a clinical update and treatment recommendations


David Perry, MD, Haematology Department, Box 234, Addenbrooke’s Hospital, Hills Road, Cambridge, CB2 0QQ, UK.
Tel.: +44 12 2325 6324; fax: +44 12 2325 6168;


Summary.  In patients with severe haemophilia and inhibitors, regular factor VIII inhibitor bypassing activity (FEIBA) prophylaxis has been shown to reduce the frequency of bleeding by up to 85% and to improve patient quality of life. FEIBA is well tolerated; the incidence of thrombotic events and of allergic reactions is extremely low. The concept of prophylaxis in haemophilia patients with inhibitors is relatively new and some clinicians may be unsure of how to use FEIBA in this context. These treatment recommendations, based on published evidence plus the collective experience of a group of haematologists (with practical knowledge of managing inhibitor patients with FEIBA prophylaxis), are intended to provide guidance to clinicians considering initiating and maintaining patients on FEIBA prophylaxis with specific focus on practical aspects of patient selection, dosing, monitoring and stop criteria.